These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 26884118)
1. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642 [TBL] [Abstract][Full Text] [Related]
3. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772 [TBL] [Abstract][Full Text] [Related]
4. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues. Cano JM; Galán R; López R Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353 [TBL] [Abstract][Full Text] [Related]
5. Clinical impact of Tuncel M; Kılıçkap S; Süslü N Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032 [TBL] [Abstract][Full Text] [Related]
6. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074 [TBL] [Abstract][Full Text] [Related]
7. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer. Chen SW; Chen YK World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496 [TBL] [Abstract][Full Text] [Related]
8. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Mitchell AL; Gandhi A; Scott-Coombes D; Perros P J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128 [TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Behr TM; Béhé MP Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605 [TBL] [Abstract][Full Text] [Related]
10. Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases. Mahajan S; Shaha A; Grewal RK Clin Nucl Med; 2018 Feb; 43(2):136-138. PubMed ID: 29261627 [TBL] [Abstract][Full Text] [Related]
11. Incidental Detection of Oxyphilic Papillary Thyroid Carcinoma by 18F-Fluorocholine PET/CT. Lalire P; Zalzali M; Garbar C; Bruna-Muraille C; Morland D Clin Nucl Med; 2016 Jun; 41(6):512-3. PubMed ID: 26914574 [TBL] [Abstract][Full Text] [Related]
12. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Treglia G; Tamburello A; Giovanella L Hormones (Athens); 2017 Oct; 16(4):362-372. PubMed ID: 29518756 [TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Béhé M; Behr TM Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727 [TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging-guided pasireotide therapy in medullary thyroid cancer with ectopic adrenocorticotropin production. Verburg FA; Anlauf M; Mottaghy FM; Karges W Clin Nucl Med; 2015 Jan; 40(1):e83-4. PubMed ID: 24999678 [TBL] [Abstract][Full Text] [Related]
15. Calcitonin-Negative Neuroendocrine Tumor of the Thyroid on 68Ga DOTANOC PET-CT. Tripathy S; Aggrawal S; Subudhi K; Kumar R; Narwal A Clin Nucl Med; 2019 Sep; 44(9):e546-e547. PubMed ID: 31283604 [TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTATOC PET/CT in Thyroid Metastases of Lung Carcinoid. Leccisotti L; Lorusso M; Giannetta E; Isidori AM; Rufini V Clin Nucl Med; 2018 Dec; 43(12):e492-e494. PubMed ID: 30358622 [TBL] [Abstract][Full Text] [Related]
17. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study. Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624 [TBL] [Abstract][Full Text] [Related]
18. How often do we see incidental 68Ga-DOTATATE thyroid uptake in PET/CT in patients with neuroendocrine tumours? Kunikowska J; Matyskiel R; Zemczak A; Strzelczyk J; Pawlak D; Królicki L; Kos-Kudła B Endokrynol Pol; 2015; 66(3):231-6. PubMed ID: 26136132 [TBL] [Abstract][Full Text] [Related]
19. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Mucha SA; Kunert-Radek J; Pomorski L Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]